Propafenone Use in Elderly Patients

Pharmacokinetics and Toxicity

• The European Society of Cardiology recommends that propafenone dosage be adjusted in elderly patients due to increased volume of distribution, reduced hepatic metabolism, and higher free fraction of the drug, which can lead to increased concentrations and toxicity 1, 2.
• The American Heart Association notes that the reduction in hepatic metabolism with age can result in higher maximum concentrations (Cmax) and prolonged half-life of propafenone, increasing the risk of toxicity 1, 3.
• The European Heart Journal reports that non-linear pharmacokinetics of propafenone can lead to disproportionate increases in plasma concentrations, which can be magnified in elderly patients 1, 3.

Monitoring and Contraindications

• The American College of Cardiology recommends careful monitoring of electrocardiogram (ECG) for signs of toxicity, such as PR and QRS prolongation, in elderly patients taking propafenone 4.
• The European Society of Cardiology advises against using propafenone in patients with structural heart disease due to the risk of proarrhythmic effects and worsening heart failure 6.
• The American Heart Association notes that propafenone can cause bradycardia, hypotension, and AV block, especially in elderly patients with sinus node dysfunction or AV block 4.

Dosing and Interactions

• The European Heart Journal recommends calculating renal function using the CKD-EPI equation and evaluating hepatic function before initiating propafenone therapy in elderly patients 1, 5.
• The American College of Cardiology advises adjusting the dosage of digoxina, warfarina, and beta-blockers when co-administered with propafenone due to increased risk of interactions 5.
• The European Society of Cardiology recommends starting with low doses of propafenone (450 mg/day) and gradually titrating as needed, with careful monitoring of ECG and clinical response 1, 5.